Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

446
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
446
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

709
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
709
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.6K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving the Goalposts in Hypertensive Risk Assessment: The AVI/LVGLS Ratio as a Sensitive Detector of Maladaptive Ventricular-Arterial Coupling.

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Long-term outcomes of ICE-guided left atrial appendage occlusion from a large single-center experience.

International journal of cardiology·2026
Same author

Successful coronary sinus reducer implantation in a patient with a pre-existing left ventricular pacing lead: a case report.

European heart journal. Case reports·2026
Same author

Functional Assessment of Hypertrophic Phenotype Cardiomyopathies Using Combined Cardiopulmonary Exercise Testing and Echocardiography: A Pilot Single-Centre Study.

Journal of clinical medicine·2026
Same author

Evaluation of left intraventricular flow dynamics using the novel non-contrast HyperDoppler technique.

European heart journal. Imaging methods and practice·2026
Same author

The Role of GH-IGF-1 Axis and S-Klotho in Atherosclerosis Natural History, Plaque Phenotype and Vulnerability: A Narrative Review.

Biomedicines·2026

Related Experiment Video

Updated: Mar 29, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K

SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge.

Angela Buonpane1,2, Marco Ciardetti3, Giancarlo Trimarchi1,2

  • 1Fondazione Toscana G. Monasterio, Ospedale del Cuore "G. Pasquinucci", 54100 Massa, Italy.

Journal of Clinical Medicine
|March 28, 2026
PubMed
Summary

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) show neutral effects on ischemic outcomes post-myocardial infarction but improve heart failure. Their vascular benefits may emerge gradually, suggesting a complex role beyond immediate hemodynamic effects.

Keywords:
heart failuremyocardial infarctionpreventive cardiologysodium–glucose co-transporter 2 inhibitors

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.7K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.7K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Biology

Background:

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are established heart failure therapies.
  • Their role in the early post-acute myocardial infarction (AMI) setting is under investigation.
  • Previous studies show neutral effects on ischemic coronary outcomes post-AMI.

Purpose of the Study:

  • To review clinical and mechanistic evidence of SGLT2i use after AMI.
  • To explore the dissociation between early clinical outcomes and underlying vascular biology.
  • To discuss the implications for SGLT2i's role in post-AMI patients.

Main Methods:

  • Review of randomized trials and meta-analyses in the post-AMI setting.
  • Analysis of experimental and translational research on SGLT2i mechanisms.
  • Synthesis of clinical and mechanistic data.

Main Results:

  • SGLT2is demonstrate favorable effects on heart failure, ventricular remodeling, and cardiometabolic parameters post-AMI.
  • Consistent neutral effects observed on ischemic coronary outcomes in clinical trials.
  • Mechanistic studies reveal SGLT2is possess anti-atherogenic properties via multiple pathways.

Conclusions:

  • A dissociation exists between early clinical trial outcomes and SGLT2i's vascular biology post-AMI.
  • Early SGLT2i effects are primarily hemodynamic and heart failure-preventive.
  • Potential anti-atherosclerotic benefits of SGLT2is may be gradual and context-dependent.